We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exposure Therapy For Veterans With PTSD And Panic Attacks

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01033136
First Posted: December 16, 2009
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
VA Office of Research and Development
  Purpose
To evaluate the feasibility, acceptability and effectiveness of Multiple Channel Exposure Therapy-Veterans (MCET-V) as a treatment for returning service members with comorbid PTSD and panic disorder (PD) in two phases. The second phase of the study will examine the effectiveness of MCET-V by comparing it to Cognitive Processing Therapy, a standard PTSD treatment.

Condition Intervention
PTSD Panic Attacks Behavioral: Multiple Channel Exposure Therapy-Veterans Behavioral: Cognitive-Processing Therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description:
Multiple Channel Exposure Therapy is a behavioral treatment that simultaneously targets panic disorder and PTSD.
Masking: Single (Outcomes Assessor)
Masking Description:
Post-treatment and follow-up assessments are conducted by an assessor masked to treatment condition.
Primary Purpose: Treatment
Official Title: Exposure Therapy for Veterans With PTSD and Panic Attacks

Further study details as provided by VA Office of Research and Development:

Primary Outcome Measures:
  • CAPS [ Time Frame: 1-week post-treatment and 3-month follow-up ]
    The CAPS is a clinician-administered assessment of PTSD.


Secondary Outcome Measures:
  • ADIS [ Time Frame: Baseline and 3-month follow-up ]
    The ADIS is a clinician-administered assessment for the presence of panic disorder and related anxiety and mood disorders.


Enrollment: 96
Actual Study Start Date: January 1, 2013
Study Completion Date: January 1, 2017
Primary Completion Date: September 30, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
MCET-V is a cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks
Behavioral: Multiple Channel Exposure Therapy-Veterans
Individual therapy design completed twice a week over a 6-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
Other Name: MCET-V
Active Comparator: Arm 2
CPT is a cognitive-behavioral treatment for persons with PTSD
Behavioral: Cognitive-Processing Therapy
Participants will be randomly assigned to receive either MCET-V or cognitive processing therapy (CPT), a standard PTSD treatment. Patients in both the MCET-V and CPT conditions will receive 12, 90-minute sessions of individual therapy twice a week over a 6-week period.
Other Name: CPT

Detailed Description:
With the increasing number of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans returning from war-zone areas, many will experience anxiety disorders such as PTSD and comorbid problems. Currently, about one in every six OIF/OEF Veterans experiences PTSD and co-occurring PD. Although effective treatments exist for treating one or the other, we do not yet have treatments that can simultaneously target PTSD and PD. Thus, recent attention has focused on the development of multi-component treatments that simultaneously address PTSD and PD. This study is the first systematic investigation of a time-limited, multi-component cognitive-behavioral treatment for Veterans with specific comorbid anxiety problems. The purpose of the second phase of the study is to evaluate the effectiveness of the multi-component cognitive-behavioral treatment in comparison to standard PTSD treatment in military personnel returning from active duty.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • being a Veteran of any era;
  • being enrolled in the TRP at the MEDVAMC, with a current diagnosis of PTSD and PD;
  • being stable on psychotropic medication for 4 weeks before study participation; and
  • being at least 18 years of age.

Exclusion Criteria:

  • active substance dependence, or bipolar or psychotic disorders;
  • severe depression and [active suicidal ideation and intent] (based on ADIS-IV & BDI-II);
  • cognitive impairment as indicated by the SLUMS; and
  • Veterans currently receiving psychosocial treatment specifically targeting PTSD or panic symptoms.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01033136


Locations
United States, Texas
Michael E. DeBakey VA Medical Center, Houston, TX
Houston, Texas, United States, 77030
Sponsors and Collaborators
VA Office of Research and Development
Investigators
Principal Investigator: Ellen Teng, PhD Michael E. DeBakey VA Medical Center, Houston, TX
  More Information

Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT01033136     History of Changes
Other Study ID Numbers: CDA2-012-09F
First Submitted: December 3, 2009
First Posted: December 16, 2009
Last Update Posted: October 12, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Panic Disorder
Anxiety Disorders
Mental Disorders